Bill Sponsor
BILLSPONSOR
Bill Sponsor
Politicians
Bills
House Bill 1076
118th Congress(2023-2024)
Preventing the Financing of Illegal Synthetic Drugs Act
Became Law
Became Law
Became Public Law 118-79 on Sep 13, 2024
Overview
Text
About Linkage
Multiple bills can contain the same text. This could be an identical bill in the opposite chamber or a smaller bill with a section embedded in a larger bill.
Bill Sponsor regularly scans bill texts to find sections that are contained in other bill texts. When a matching section is found, the bills containing that section can be viewed by clicking "View Bills" within the bill text section.
Bill Sponsor is currently only finding exact word-for-word section matches. In a future release, partial matches will be included.
About Linkage
Multiple bills can contain the same text. This could be an identical bill in the opposite chamber or a smaller bill with a section embedded in a larger bill.
Bill Sponsor regularly scans bill texts to find sections that are contained in other bill texts. When a matching section is found, the bills containing that section can be viewed by clicking "View Bills" within the bill text section.
Bill Sponsor is currently only finding exact word-for-word section matches. In a future release, partial matches will be included.
Jump To
H. R. 1076 (Enrolled-Bill)
H. R. 1076


One Hundred Eighteenth Congress of theUnited States of America

AT THE SECOND SESSION

Begun and held at the City of Washington on Wednesday,
the third day of January, two thousand and twenty-four

an act

    To require the Comptroller General of the United States to carry out a study on the trafficking into the United States of synthetic drugs, and related illicit finance, and for other purposes.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. Short title.

This Act may be cited as the “Preventing the Financing of Illegal Synthetic Drugs Act”.

SEC. 2. Findings.

The Congress finds the following:

(1) According to the Center for Disease Control and Prevention, over 107,000 people in the United States died from drug overdoses or drug poisonings in the 12-month period ending January 2022, with 67 percent of those deaths involving synthetic opioids like fentanyl.

(2) According to the United National Office of Drugs and Crime (UNODC) in its “Synthetic Drug Strategy 2021-2025”, the number of synthetic drugs, also called New Psychoactive Substances, has increased 631 percent since 2009, with traffickers introducing an average of 80 new substances to the illicit drug market each year from 2009-2019.

(3) In October 2022, F. Michael McDaniel, director of the Houston High Intensity Drug Trafficking Areas (HITDA) program testified in Congress that one kilogram of fentanyl can produce one million counterfeit pills containing one milligram of fentanyl, saying, “Currently in Houston, Texas, you can buy a kilogram of fentanyl for an average price of $25,000 to $30,000. This same kilogram of fentanyl in Culiacán (Mexico) could be purchased at an average price of $13,500. Currently, the price of a fentanyl pill in Houston ranges from $6 to $65. Therefore, an illicit investment of $30,000 or less could result in a return of $6 to $32.5 million.”.

(4) According to Celina B. Realuyo, Adjunct Professor, The George Washington University Elliott School of International Affairs, in March 2022 Congressional testimony, “Financing is essential to support and sustain the command and control, personnel, arms, communications, logistics and operations of organized crime groups. For this reason, following the money trail and depriving criminals of illicit financial flows can disrupt and disable these networks.”.

SEC. 3. GAO study on synthetic drugs trafficking.

(a) Study.—The Comptroller General of the United States shall carry out a study on illicit financing in connection with the trafficking of synthetic drugs, including fentanyl and methamphetamine, fentanyl- and methamphetamine-related substances, Captagon, and fentanyl and methamphetamine precursors, including—

(1) the business of the trafficking of synthetic drugs and related illicit finance, such as the participation of transnational criminal organizations and terror syndicates and their notable trafficking corridors, including source and transit countries;

(2) the business models used by these transnational criminal organizations, including U.S. domestic and foreign activities for precursor purchase or production, movement along the supply chain, manufacture of the completed product, marketing, distribution, sales, and return of proceeds;

(3) the overlap of the business model of human trafficking and the trafficking of synthetic drugs and related illicit finance;

(4) the use of online illicit drug markets and the use of social media for the marketing, sale, and payment for synthetic drugs;

(5) financial methods used by such transnational criminal organizations, including—

(A) payment;

(B) money laundering; and

(C) repatriation of proceeds;

(6) the use of social media applications like Snap Chat, Discord, and Facebook and payment applications like CashApp to facilitate financial transactions for synthetic drug trafficking, especially among young people; and

(7) U.S. Government activities to combat illicit finance related to the trafficking of synthetic drugs, including—

(A) interagency collaboration, including personnel detailed to other agencies to support the effort to combat synthetic drugs trafficking and related illicit finance;

(B) intergovernmental collaboration;

(C) intersectoral collaboration with the private sector, including the business and non-governmental communities; and

(D) identified gaps or resource deficiencies in combating the trafficking of synthetic drugs and related illicit finance in the coordination and collaboration activities described in subparagraphs (A) through (C).

(b) Report required.—Not later than the end of the 1-year period beginning on the date of enactment of this Act, the Comptroller General shall issue a report to the Congress containing all findings and determinations made in carrying out the study required under subsection (a).

Attest:





Speaker of the House of Representatives.  

Attest:





Vice President of the United States and   
President of the Senate.